RxDoctor Payments Data

Wanida Walker

Nurse Practitioner · Tampa, FLNPI 1205375045

Payments from drug & device makers

$5,460in general payments, 2019–2025

Across 131 payments — averaging $41.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$2K
  • Theratechnologies Inc.$385
  • Janssen Scientific Affairs, LLC$199
  • Dynavax Technologies Corporation$145
  • Johnson & Johnson$107
  • plus $114 from 6 others

What the payments were for

  • Food & beverage$5,33098%
  • Education$1302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,460 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$8,360
Medicare patients
29
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala384$1,498,127
JulucaDolutegravir/Rilpivirine119$390,963
TivicayDolutegravir Sodium152$384,369
GenvoyaElviteg/Cob/Emtri/Tenof Alafen90$353,037
DovatoDolutegravir Sodium/Lamivudine87$254,667
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf51$217,859
DescovyEmtricitabine/Tenofov Alafenam87$198,023
TriumeqAbacavir/Dolutegravir/Lamivudi52$192,450
OdefseyEmtricitab/Rilpiviri/Tenof Ala25$92,275
IsentressRaltegravir Potassium32$66,865
PrezcobixDarunavir/Cobicistat19$36,205
Maraviroc23$26,449
EdurantRilpivirine Hcl18$25,296
Darunavir28$12,526
Atovaquone12$8,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$2,188$2,049,187561 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato, Triumeq$2,322$1,222,449410 claims
MerckIsentress$21$66,86532 claims
Johnson & JohnsonPrezcobix$107$36,20519 claims
Janssen Scientific Affairs, LLCEdurant$199$25,29618 claims
GSKTrelegy Ellipta$12$6,42112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →